Blog Viewer

On November 13, the Department of Transportation (DOT) amended its drug-testing program regulation to: add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine as an initial test analyte; and, remove methylenedioxyethylamphetamine as a confirmatory test analyte. The revision of the drug-testing panel harmonizes DOT regulations with the revised Health and Human Services (HHS) Mandatory Guidelines established by the U.S. Department of HHS for federal drug-testing programs for urine testing. The final rule clarifies certain existing drug- testing program provisions and definitions, makes technical amendments, and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. This rule is effective on January 1, 2018.

A copy of the rule can be found on the APGA Community. For questions on this article, please contact John Erickson of APGA staff by phone at 202-464-0834 or by email at jerickson@apga.org.